|Dr. Daniel P. Gold Ph.D.||Pres, CEO & Director||841.8k||N/A||63|
|Mr. Brian G. Drazba CPA||Sec. & CFO||N/A||N/A||56|
|Mr. David M. Urso Esq., J.D.||Sr. VP of Corp. Devel. and Gen. Counsel||501.36k||N/A||53|
|Dr. Robert D. Mass M.D.||Chief Medical Officer||242.54k||N/A||63|
|Dr. Karen E. Potts Ph.D.||Sr. VP of Regulatory Affairs||N/A||N/A||54|
MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The companys clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
MEI Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.